Name: Ziv-aflibercept Synonyms: VEGF trap; Zaltrap
MECHANISM OF ACTION
Ziv-aflibercept is a soluble receptor that binds to endogenous human vascular endothelial growth factor (VEGF)-A, human VEGF-B, and human purified growth inhibitory factor (PGIF) inhibiting binding and activation of the cognate receptors. This inhibition results in decreased neovascularization and vascular permeability.
PHARMACOKINETICS
Free ziv-aflibercept concentrations appear to exhibit linear pharmacokinetics between 2 mg/kg and 9 mg/kg. Following a 4 mg/kg intravenous (IV) dose every 2 weeks, the elimination half-life of free zivaflibercept is approximately 6 days. Steady-state concentration of free ziv-aflibercept was reached by the second dose.
Selected therapeutic regimens of ziv-aflibercept appear in Table 1 . 
MECHANISM OF ACTION
Vincristine sulfate liposomal injection (VSLI) is an extended release formulation of vincristine, which is the active moiety. Vincristine binds to tubulin, inhibiting microtubule formation. The resulting metaphase arrest causes disruption of the mitotic spindle. Vincristine may also interfere with nucleic acid and protein synthesis by blocking glutamic acid utilization. It is specific for the M and S phases of the cell cycle.
PHARMACOKINETICS
VSLI contains vincristine encapsulated in a rigid, lipid bilayer of sphingomyelin that releases the drug slowly, maintaining drug levels for prolonged periods of time. It has been proposed that encapsulating vincristine in nanoparticle carriers increases the circulation time of the drug and increases the amount of drug that penetrates and accumulates at the tumor site to enhance the cytotoxic effect. The volume of distribution (V d ) is 2.7 L; the elimination half-life is 45 hours. Vincristine is metabolized hepatically, primarily by CYP3A4. Excretion is primarily fecal (69%); less than 8% of the drug is excreted in the urine.
Selected therapeutic regimens of liposomal vincristine appear in Table 2 . PREPARATION 1. Follow institutional policies for handling of hazardous drugs. 2. VSLI is supplied as a 3 vial kit. After preparation, each vial contains 0.16 mg/mL vincristine sulfate.
Preparation:
a. Fill a water bath with at least 8 cm of water and maintain this level throughout the procedure. b. Preheat the water bath to 63°C to 67°C (145°F to 153°F) and maintain this temperature throughout the procedure. c. Vent the sodium phosphate injection vial through a 0.2 micron filter. d. Withdraw 1 mL of sphingomyelin/cholesterol liposome injection and inject it into the sodium phosphate injection vial. e. Withdraw 5 mL of vincristine sulfate injection and inject it into the sodium phosphate vial. 
DRUG INTERACTIONS
No formal drug interaction studies have been performed with VLSI; however it is expected to interact with drugs known to interact with vincristine. Vincristine is a CYP3A4 substrate. Inhibitors of CYP3A4 might increase vincristine concentrations; inducers of CYP3A4 might decrease vincristine concentrations.
TOXICITIES
Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. 
THERAPY CONSIDERATIONS
Data from limited number of controlled and noncontrolled trials suggest that vardenafil may reduce the severity, duration, and frequency of attacks with RP. Larger, controlled trials compared with traditional therapy are needed to establish the benefit and safety of vardenafil in the management of RP.
